170 related articles for article (PubMed ID: 29930330)
1. Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy.
Stangenberg S; Saad S; Schilter HC; Zaky A; Gill A; Pollock CA; Wong MG
Sci Rep; 2018 Jun; 8(1):9423. PubMed ID: 29930330
[TBL] [Abstract][Full Text] [Related]
2. Semicarbazide-sensitive amine oxidase inhibition ameliorates albuminuria and glomerulosclerosis but does not improve tubulointerstitial fibrosis in diabetic nephropathy.
Wong MY; Saad S; Wong MG; Stangenberg S; Jarolimek W; Schilter H; Zaky A; Gill A; Pollock C
PLoS One; 2020; 15(6):e0234617. PubMed ID: 32555665
[TBL] [Abstract][Full Text] [Related]
3. Lysyl oxidase like-2 contributes to renal fibrosis in Col4α3/Alport mice.
Cosgrove D; Dufek B; Meehan DT; Delimont D; Hartnett M; Samuelson G; Gratton MA; Phillips G; MacKenna DA; Bain G
Kidney Int; 2018 Aug; 94(2):303-314. PubMed ID: 29759420
[TBL] [Abstract][Full Text] [Related]
4. The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis.
Schilter H; Findlay AD; Perryman L; Yow TT; Moses J; Zahoor A; Turner CI; Deodhar M; Foot JS; Zhou W; Greco A; Joshi A; Rayner B; Townsend S; Buson A; Jarolimek W
J Cell Mol Med; 2019 Mar; 23(3):1759-1770. PubMed ID: 30536539
[TBL] [Abstract][Full Text] [Related]
5. Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse.
Nguyen LT; Saad S; Shi Y; Wang R; Chou ASY; Gill A; Yao Y; Jarolimek W; Pollock CA
Sci Rep; 2021 Jun; 11(1):12437. PubMed ID: 34127702
[TBL] [Abstract][Full Text] [Related]
6. Ethyl pyruvate ameliorates albuminuria and glomerular injury in the animal model of diabetic nephropathy.
Ju KD; Shin EK; Cho EJ; Yoon HB; Kim HS; Kim H; Yang J; Hwang YH; Ahn C; Oh KH
Am J Physiol Renal Physiol; 2012 Mar; 302(5):F606-13. PubMed ID: 22129969
[TBL] [Abstract][Full Text] [Related]
7. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
Jha JC; Thallas-Bonke V; Banal C; Gray SP; Chow BS; Ramm G; Quaggin SE; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
Diabetologia; 2016 Feb; 59(2):379-89. PubMed ID: 26508318
[TBL] [Abstract][Full Text] [Related]
8. Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes.
Ma G; Allen TJ; Cooper ME; Cao Z
Kidney Int; 2004 Sep; 66(3):1090-8. PubMed ID: 15327403
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan Mitigates High-Glucose-Induced Injury in Renal Glomerular Endothelial Cells (rGECs) and Albuminuria in Diabetes Mice.
Zhan X; Chen W; Chen J; Lei C; Wei L
Chem Res Toxicol; 2021 Sep; 34(9):2079-2086. PubMed ID: 34464088
[TBL] [Abstract][Full Text] [Related]
10. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
[TBL] [Abstract][Full Text] [Related]
11. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy.
Mifsud S; Kelly DJ; Qi W; Zhang Y; Pollock CA; Wilkinson-Berka JL; Gilbert RE
Nephron Physiol; 2003; 95(4):p83-91. PubMed ID: 14694265
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase inhibition ameliorates experimental diabetic nephropathy.
Huang L; Haylor JL; Hau Z; Jones RA; Vickers ME; Wagner B; Griffin M; Saint RE; Coutts IG; El Nahas AM; Johnson TS
Kidney Int; 2009 Aug; 76(4):383-94. PubMed ID: 19553913
[TBL] [Abstract][Full Text] [Related]
13. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
[TBL] [Abstract][Full Text] [Related]
14. Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis.
Yao Y; Findlay A; Stolp J; Rayner B; Ask K; Jarolimek W
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628342
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.
Koya D; Haneda M; Nakagawa H; Isshiki K; Sato H; Maeda S; Sugimoto T; Yasuda H; Kashiwagi A; Ways DK; King GL; Kikkawa R
FASEB J; 2000 Mar; 14(3):439-47. PubMed ID: 10698958
[TBL] [Abstract][Full Text] [Related]
16. C-peptide ameliorates renal injury in type 2 diabetic rats through protein kinase A-mediated inhibition of fibronectin synthesis.
Xu S; Jiang Y; Wang H; Wang Z; Liu H; Peng L; Fang Q; Deng T; You J; Zhou X; Zhang W; Lou J
Biochem Biophys Res Commun; 2015 Mar; 458(3):674-680. PubMed ID: 25684188
[TBL] [Abstract][Full Text] [Related]
17. 17beta-Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney.
Mankhey RW; Wells CC; Bhatti F; Maric C
Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R769-77. PubMed ID: 16931652
[TBL] [Abstract][Full Text] [Related]
18. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
[TBL] [Abstract][Full Text] [Related]
19. LOXL2 Inhibition Paves the Way for Macrophage-Mediated Collagen Degradation in Liver Fibrosis.
Klepfish M; Gross T; Vugman M; Afratis NA; Havusha-Laufer S; Brazowski E; Solomonov I; Varol C; Sagi I
Front Immunol; 2020; 11():480. PubMed ID: 32296422
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of Lysyl Oxidases Expression in Diabetic Nephropathy and Renal Cell Carcinoma.
Añazco C; Cerro S; Pereira N; Rojas C; Torres Á; Vidal-Beltrán I
Curr Drug Targets; 2021; 22(17):1916-1925. PubMed ID: 34879794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
